Clinical Trial Update: Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pharmacodynamic effects of BI 1026706 vs placebo on endotoxin-induced inflammatory response in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• BI 1026706 (BI 1026706)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Healthy | Phase 1 | Status: COMPLETED | Results posted: 2019-07-10